Trials / Withdrawn
WithdrawnNCT01893658
Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators goal is to evaluate the role of XOLAIR® in treatment of Acute Tubulointerstitial Nephritis (AIN) with the goal of shortening the duration and dose of prednisone for treatment of drug-induced AIN. Currently there is no good treatment for drug-induced AIN. Prednisone is the standard treatment but is associated with many side-effects when used long-term and at high doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Omalizumab | administration of a single dose together with the standard treatment |
| DRUG | Prednisone | standard treatment |
Timeline
- Start date
- 2018-06-01
- Primary completion
- 2018-09-28
- Completion
- 2018-09-28
- First posted
- 2013-07-09
- Last updated
- 2018-12-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01893658. Inclusion in this directory is not an endorsement.